Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan.
Tomokazu ShojiRyusei MutoHaruhisa FukudaYuichi MurakiKeishi KawataAkazawa ManabuPublished in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2022)
In the definitive therapy period, MRSA bacteremia had higher incremental costs and greater use of healthcare resources. In addition, the incremental costs in aggressive facilities were lower than those in passive facilities.
Keyphrases
- methicillin resistant staphylococcus aureus
- healthcare
- antimicrobial resistance
- staphylococcus aureus
- public health
- gram negative
- health insurance
- electronic health record
- big data
- radiation therapy
- stem cells
- machine learning
- bone marrow
- mesenchymal stem cells
- health information
- social media
- data analysis
- artificial intelligence
- affordable care act